June 19-22, 2017 | San Diego, CA

Partnering & Education: Monday - Thursday
Exhibition: Tuesday - Thursday




Albert Einstein

Sr. Scientist DevOps,
CompanyName

  • Creating next generation treatments & cures
  • Delivering value to patients & our economy

View Profile




Grace Kelly

Chief Maketing Officer,
CompanyName

  • Creating next generation treatments & cures
  • Delivering value to patients & our economy

View Profile




Mister T

Chief Pitier of Fools,
CompanyName

  • Creating next generation treatments & cures
  • Delivering value to patients & our economy

View Profile


partnering-webinar-headshot-davidthomas.png

David Thomas, CFA
Senior Director of Industry Research, BIO

David is currently Senior Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry

Row 1: Full-Width Top

Use this section to add content in a Full-Width column


Request Report

3rd annual EMERGING THERAPEUTIC COMPANY INVESTMENT AND DEAL TRENDS 2007-2016

Fill out the form to request your copy of BIO's newest report.

Includes:

  • U.S. Venture Capital and Public Offerings, 2007-2016
  • Global Licensing and Acquisitions 2007-2016
  • Current Pipeline for Emerging Companies

Report Highlights
More than 90% of our industry is made up of small companies. This report captures stats for companies with less than a $1 billion in sales and covers six main areas: venture funding, public investment (IPOs and follow-ons), licensing, M&A, and the clinical pipeline (partnered vs. partnered).

  • Pipeline: Emerging companies are responsible for 70% of the global clinical pipeline and 84% of all Orphan-designated programs.
  • Venture Capital: US companies raised $5.5 billion in venture capital, driven mainly by immuno-oncology and neurodegenerative disease companies remain key drivers.
  • Venture Capital: Series A financing increased to a record $1.9 billion in 2016.
  • IPOs: Since the signing of the JOBS Act five years ago, more than 200 emerging biotech companies have gone public.
  • Follow-On Public Offerings: US emerging companies raised 56% less in 2016 vs. 2015 through FOPOs, reflective of the tough public market for biotech in 2016.
  • Licensing: Large deals (over $1B in potential payments) reached a record high for Preclinical-stage assets in 2016
  • Acquisitions: The number of acquisitions of R&D-stage companies reached the highest level in eight years, but the total amount paid was only half the level seen in 2015.

Don’t miss the author discuss the findings of the report at the BIO International Convention in the “State of the Innovation Industry” session June 19 in San Diego!

BIO's David Thomas, Senior Director of Industry Research, will present emerging therapeutic company trends across venture funding and public investment (IPOs and follow-ons), as well as small company contributions to the global clinical pipeline and recent drug approvals. Register for the BIO International Convention today!

partnering-webinar-headshot-davidthomas.png

David Thomas, CFA
Senior Director of Industry Research, BIO

David is currently Senior Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.

4-Column Content

Add a description, link, or some more info here...

4-Column Content

Add a description, link, or some more info here...

4-Column Content

Add a description, link, or some more info here...

4-Column Content

Add a description, link, or some more info here...

4-Column Code Box [Resource]

This content spans 12 columns, but the row below is broken up into 1/4 columns for an easy copy/paste into any other editable area

1st Column

2nd Column

3rd Column

4th Column